We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Journal of Comparative Effectiveness Research
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Priority Paper Evaluation

Muscle wasting is associated with reduced exercise capacity and advanced disease in patients with chronic heart failure

    Akihiko Kato

    Blood Purification Unit, Hamamatsu University Hospital, 1-20-1 Handayama, Higashi-ku, Hamamatsu, Shizuoka, 431-3192, Japan.

    Search for more papers by this author

    Email the corresponding author at a.kato@hama-med.ac.jp

    Published Online:4 Nov 2013https://doi.org/10.2217/fca.13.74

    Abstract

    Evaluation of: Fülster S, Tacke M, Sandek A et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating comorbidities aggravating heart failure (SICA-HF). Eur. Heart J. 34(7), 512–519 (2013). Muscle atrophy of the lower limbs is a comorbidity that can develop in advanced stages of chronic heart failure (HF). The article by Fülster et al. prospectively examined the association of muscle mass volume and muscle strength, gait speed, walking distance and treadmill performance in 200 stable HF patients. Muscle wasting was legitimately defined as the appendicular muscle mass two standard deviations below the mean of a healthy reference group. Muscle wasting was detected in 39 (19.5%) patients. Patients with muscle atrophy had significantly lower values for muscle strength, as well as lower total peak oxygen consumption (1173 ± 433 vs 1622 ± 456 ml/min), lower exercise time (7.7 ± 3.8 vs 10.2 ± 2.0 min; both p < 0.001) and lower left ventricular ejection fraction (p = 0.05). In addition, the distance walked and gait speed were also lower in patients with muscle wasting than those without (p < 0.05). Logistic regression analyses revealed that muscle wasting was independently associated with reduced peak oxygen consumption after adjustment for cofounders. These findings suggest that skeletal muscle wasting is common in chronic HF patients and is associated with worse exercise capacity and reduced left ventricular ejection fraction.

    Papers of special note have been highlighted as: ▪ of interest

    References

    • 1  Mancini DM, Walter G, Reichek N et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation85,1364–1373 (1992).Crossref, Medline, CAS, Google Scholar
    • 2  Anker SD, Ponikowski PP, Clark AL et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. Eur. Heart J.20,683–693 (1999).Crossref, Medline, CAS, Google Scholar
    • 3  Anker SD, Swan JW, Volterrani M et al. The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure. Eur. Heart J.18,259–269 (1997).Crossref, Medline, CAS, Google Scholar
    • 4  Fülster S, Tacke M, Sandek A et al. Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF). Eur. Heart J.34,512–519 (2013).Crossref, Medline, CAS, Google Scholar
    • 5  Cruz-Jentoft AJ, Baeyens JP, Bauer JM et al. Sarcopenia: European consensus on definition and diagnosis. Age Ageing39,412–423 (2010).Crossref, Medline, Google Scholar
    • 6  Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet349,1050–1053 (1997).Crossref, Medline, CAS, Google Scholar
    • 7  Landi F, Lipertoni R, Russo A et al. Sarcopenia as a risk factor for falls in elderly individuals. Results from the iISIRENTE study. Clin. Nutr.31,652–658 (2012).Crossref, Medline, Google Scholar
    • 8  Landi F, Cruz-Jentoft AJ, Liperoti R et al. Sarcopenia and mortality risk in frail older persons aged 80 years and older: results from iISIRENTE study. Age Ageing42,203–209 (2913).Crossref, Google Scholar
    • 9  Gerber Y, Melton LJ, Weston SA et al. Osteoporotic fractures and heart failure in the community. Am. J. Med.124,418–425 (2011).▪ The association of heart failure (HF) with osteoporotic fractures was approximately as strong before as after the diagnosis of HF, and nearly entirely attributable to hip fractures in the community.Crossref, Medline, Google Scholar
    • 10  Janssen SP, Gayen-Ramirez G, Van den Bergh A et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation111,996–1005 (2005).Crossref, Medline, CAS, Google Scholar
    • 11  Schaap LA, Saskia MF, Deeg DJH et al. Inflammatory markers and loss of muscle mass (sarcopenia) and strength. Am. J. Med.119,526.e9–526.e17 (2006).Crossref, Medline, Google Scholar
    • 12  Jug B, Salobir BG, Vene N et al. Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure. Heart Vessels24,271–276 (2009).Crossref, Medline, Google Scholar
    • 13  Venture-Clapier R, Mettauer B, Bigard X. Beneficial effects of endurance training on cardiac and skeletal muscle energy metabolism in heart failure. Cardiovasc. Res.73,10–18 (2007).Crossref, Medline, Google Scholar
    • 14  Gielen S, Sandri M, Kozarez I et al. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age. The randomized Leipzig exercise intervention in chronic heart failure and aging catabolism study. Circulation125,2716–2727 (2012).▪ MuRF-1, a component of the ubiquitin–proteasome system involved in muscle proteolysis, is increased in the skeletal muscle of patients with HF. Endurance training for 4 weeks reduced MuRF-1 mRNA expression by -32.8% in patients aged ≤55 years and by -37.0% in patients aged ≥65 years. The findings suggest that exercise training blocks ubiquitin–proteasome system activation in both younger and older patients with chronic HF.Crossref, Medline, CAS, Google Scholar
    • 15  Kitzman DW, Brubaker PH, Herrington DM et al. Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial. J. Am. Coll. Cardiol. doi:10.1016/j.jacc.04.033 (2013) (Epub ahead of print).Google Scholar
    • 16  Breitbart A, Auger-Messier M, Molkentin JD et al. Myostatin from the heart: local and systemic actions in cardiac failure and muscle wasting. Am. J. Physiol. Circ. Physiol.300,H1973–H1982 (2011).Crossref, Medline, CAS, Google Scholar
    • 17  Heineke J, Auger-Messier M, Xu J et al. Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation121,419–425 (2010).▪ Heart-specific deletion of the myostatin gene in mice does not alter basal heart size or secondarily affect skeletal size; it prevents atrophy of skeletal muscle characteristics of wasting during pressure overload-induced HF, suggesting an endocrine role of myostatin released from cardiomyocytes in skeletal muscle wasting in HF.Crossref, Medline, CAS, Google Scholar
    • 18  George I, Bish LT, Kamalakkannan G et al. Myostatin activation in patients with advanced heart failure and after mechanical loading. Eur. J. Heart Fail.12,443–453 (2010).Crossref, Google Scholar
    • 19  Gruson D, Ahn SA, Ketelslegers JM et al. Increase plasma myostatin in heart failure. Eur. J. Heart Fail.13,734–736 (2011).Crossref, Medline, CAS, Google Scholar
    • 20  Attie KM, Borgstein NG, Yang Y et al. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers. Muscle Nerve47,416–423 (2013).Crossref, Medline, CAS, Google Scholar
    • 21  Lenk K, Schur R, Linke A et al. Impact of exercise training on myostatin expression in myocardium and skeletal muscle in a chronic heart failure model. Eur. J. Heart Fail.11,342–348 (2009).Crossref, Medline, CAS, Google Scholar
    • 22  Shyu KG, Lu MJ, Wang BW et al. Myostatin expression in ventricular myocardium in a rat model of volume-overload heart failure. Eur. J. Clin. Invest.36,713–719 (2006).Crossref, Medline, CAS, Google Scholar
    • 23  Rozentryt P, von Haehling S, Lainscak M et al. The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study. J. Cachexia Sarcopenia Muscle1,35–42 (2010).Crossref, Medline, Google Scholar
    • 24  Masson S, Marchioli R, Mozaffarian D et al. Plasma n-3 polyunsaturated fatty acids in chronic heart failure in the GISSI-Heart Failure Trial: relation with fish intake, circulating biomarker, and mortality. Am. Heart J.165,208–214 (2013).▪ Circulating n-3 polyunsaturated fatty acid levels in patients with chronic HF mainly depend on dietary fish consumption. Three-month treatment with n-3 polyunsaturated fatty acids markedly increased circulating eicosapentaenoic acid and docosahexaenoic acid, independently of fish intake, and lowered oxidative stress markers. Low eicosapentaenoic acid levels are inversely related to total mortality in patients with chronic HF.Crossref, Medline, CAS, Google Scholar